Ter Arkh. 2025 Nov 11;97(10):859-866. doi: 10.26442/00403660.2025.10.203462.
ABSTRACT
BACKGROUND: Despite the variety of antidiabetic therapies, many patients with type 2 diabetes (T2D) do not achieve optimal glycemic control. Therefore, there is a need to develop additional methods for managing T2D, including ones that regulate the gut microbiome.
AIM: To assess the effect of AntiAGE-Biom probiotic on metabolic parameters in T2D patients during 3 months of therapy.
MATERIALS AND METHODS: A randomized, double-blind, placebo-controlled, single-center study included patients with T2D with glycated hemoglobin – HbA1c<7,5% on stable antidiabetic therapy. Patients were randomized into groups receiving AntiAGE-Biom and placebo. The primary endpoint was the change in HbA1c from baseline, secondary endpoints included the dynamics in biochemical and anthropometric parameters, body composition, as well as HOMA-IR index.
RESULTS: The study included 40 patients with T2D (n=20 in each group). There was a trend towards a decrease in HbA1c in AntiAGE-Biom group, that did not reach statistical significance. The use of the probiotic improved the body composition after 3 months: reduced the percentage of fat in men and a subgroup of patients with an initial HbA1c≥ 6.5%; also increased skeletal muscle mass and lean mass in the trunk segment in men (р<0,05).
CONCLUSION: AntiAGE-Biom probiotic helps to maintain metabolic control and significantly improve body composition in T2D patients with initial HbA1c<7.5%.
PMID:41235517 | DOI:10.26442/00403660.2025.10.203462
